Core Viewpoint - Hendi Pharmaceutical (301211) forecasts a significant decline in net profit for 2025, estimating a range of 31 million to 39 million yuan, representing a year-on-year decrease of 57.4% to 66.14% [2] Group 1: Financial Performance - The company anticipates a net profit of 31 million to 39 million yuan for 2025, indicating a substantial decline compared to previous years [2] - The projected decline in net profit is attributed to intensified market competition for its main product, ibuprofen raw materials, and certain specialty raw materials, leading to a decrease in gross margin [2] Group 2: Market Conditions - Increased competition in the market for ibuprofen and specialty raw materials is a key factor contributing to the expected decline in profitability [2] - A reduction in interest income from cash management due to falling interest rates is also impacting the company's financial outlook [2]
亨迪药业2025年净利预降57.4%至66.14%